The SCCC-Upstate is a merger of two successful legacy CCOPs known as Southeast Cancer Control Consortium, Inc. (SCCC) and Upstate Carolina (hereafter the Consortium) comprised of 23 components and 63 sub-components, located in a five-state area of the Southeast US (GA, NC, SC, TN, and VA) with a nonclinical Administrative Office (AO) in Winston-Salem, NC. The Consortium eliminates a critical barrier by supplying service to the rural southeastern area. The AO provides expertise, regulatory support, training, education, and principal investigators to enable small rural community hospitals, private practices, and solo practitioners the ability to provide clinical trials to ther patients. With this structure, rural centers will be able to translate academic-generated concepts to the real world. Economic constraints prohibit most hospitals and private practices from allocating the required resources to conduct research independently. This structure has been successful in supporting rural communities for the past 30 years. This was the vision of Charles L Spurr, MD that has been carried on by Drs. Atkins and Bearden to make clinical trials available in the patient's home community. Each component has a responsible investigator and coordinator to organize and promote clinical research participation. Over 232 investigators and 140 research staff located at 86 treatment centers are involved in the delivery of research in a variety of community settings. The vast geographical area improves the opportunity to increase access of NCI-sponsored clinical trials. The long-term objectives are to: 1) provide cutting edge clinical trials;2) implement programs to enhance cancer care delivery;3) build on existing relationships and establish new collaborations;and 4) actively enroll participants to clinical trials. The catchment area of the components is over 9.5 million, with diverse demographics including a significant African American population. NCI support of this grant will allow restricted federal dollars to be maximized over a vast rural geographic area reaching rural and medically underserved populations.

Public Health Relevance

Advances in oncology can only be made through the execution of well-designed clinical trials, and these advances will lead to improved survival and public health. This 23-member Consortium has the strength and capability to contribute to this outcome. Through the combined strength of this consortium, clinical trials are accessible to small, rural, medically underserved Appalachia communities of the Southeast.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
1UG1CA189858-01
Application #
8790811
Study Section
Special Emphasis Panel (ZCA1-RTRB-E (M1))
Program Officer
Xie, Heng
Project Start
2014-08-01
Project End
2019-07-31
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
1
Fiscal Year
2014
Total Cost
$2,976,856
Indirect Cost
$72,577
Name
Southeast Cancer Control Consortium
Department
Type
DUNS #
876940532
City
Winston-Salem
State
NC
Country
United States
Zip Code
27104
Li, Megan; Mulkey, Flora; Jiang, Chen et al. (2018) Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res 24:4734-4744
Persky, Daniel O; Li, Hongli; Rimsza, Lisa M et al. (2018) A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. Am J Hematol 93:486-493
Gajra, Ajeet; McCall, Linda; Muss, Hyman B et al. (2018) The preference to receive chemotherapy and cancer-related outcomes in older adults with breast cancer CALGB 49907 (Alliance). J Geriatr Oncol 9:221-227
Woyach, Jennifer A; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med 379:2517-2528
Fadelu, Temidayo; Zhang, Sui; Niedzwiecki, Donna et al. (2018) Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance). J Clin Oncol 36:1112-1120
West, Howard L; Moon, James; Wozniak, Antoinette J et al. (2018) Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer 19:84-92
Guercio, Brendan J; Zhang, Sui; Niedzwiecki, Donna et al. (2018) Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance). PLoS One 13:e0199244
Van Blarigan, Erin L; Fuchs, Charles S; Niedzwiecki, Donna et al. (2018) Marine ?-3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance). Cancer Epidemiol Biomarkers Prev 27:438-445
Henry, N Lynn; Unger, Joseph M; Schott, Anne F et al. (2018) Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. J Clin Oncol 36:326-332
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504

Showing the most recent 10 out of 36 publications